NeuroSense targets March 2027 PrimeC Canada application
After acceptance, Health Canada’s standard review target for an NDS is approximately 300 calendar days, and the release cites about 4,000 Canadians living with ALS.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NeuroSense Therapeutics Ltd. plans to add newly generated neurofilament light chain (NfL) analysis and additional unpublished Phase 2b data to its planned New Drug Submission to Health Canada for PrimeC, with a March 2027 filing target replacing the previously announced December 2026 timetable. Health Canada confirmed it has no concerns with the revised timing. NeuroSense reported a greater NfL reduction among PrimeC-treated participants than among placebo participants, with a more pronounced effect in participants with higher baseline functionality; further statistical analyses are underway. The planned submission would be PrimeC’s first marketing application in any jurisdiction.
After acceptance of the submission for review, Health Canada’s standard review target for an NDS is approximately 300 calendar days. If approved, PrimeC would address a population of approximately 4,000 Canadians living with ALS, with approximately 1,000 new diagnoses each year. NeuroSense is advancing discussions with potential commercialization partners in Canada and preparing for its FDA-cleared U.S. Phase 3 PARAGON trial while working with the FDA on an optimized study design.
Filing Explained
This Form 6-K makes the report part of several existing Form S-8 and Form F-3 registration statements as of its submission date, except for the fifth paragraph of Exhibit 99.1; later filings or reports may supersede it.
Key Figures
Key Terms
New Drug Submission (NDS) regulatory
neurofilament light chain (NfL) medical
fixed-dose combination medical
extended-release oral formulation medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does NRSN plan to submit PrimeC to Health Canada?
What new data will NRSN include in PrimeC’s Canadian submission?
How long is Health Canada’s standard review target for an NDS?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of November 2026
Commission File Number: 001-41084
NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)
NeuroSense Therapeutics Ltd.
2 Ha-Tidhar Street
Ra’anana 4366504, Israel
+972-9- 7996183
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Explanatory Note
Attached is the Company’s press release regarding NeuroSense strengthening of PrimeC Canadian ALS submission with new NfL data, furnished herewith as Exhibit 99.1.
This Report on Form 6-K (other than the fifth paragraph in Exhibit 99.1) is hereby incorporated by reference into registrant’s Registration Statements on Form S-8 (File No. 333-262480 and 333-289658) and Form F-3 (File No. 333-260338, 333-283656, 333-284051, 333-291122 and 333-293060), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished
Exhibit Index
| Exhibit No. | Description | |
| 99.1 | Press Release dated November 2, 2026 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NeuroSense Therapeutics Ltd. | ||
| Date: November 2, 2026 | By: | /s/ Alon Ben-Noon |
| Alon Ben-Noon | ||
| Chief Executive Officer | ||
2
Exhibit 99.1
NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
Expanded package to include new neurofilament light chain (NfL) analysis; Health Canada confirms March 2027 filing timeline
Submission would be PrimeC’s first marketing application in any jurisdiction, potentially addressing approximately 4,000 Canadians living with ALS
CAMBRIDGE, Mass., Nov. 2, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for neurodegenerative diseases, today announced plans to incorporate newly generated data into its New Drug Submission (NDS) to Health Canada for PrimeC, its lead investigational therapy for amyotrophic lateral sclerosis (ALS). The NDS would be PrimeC’s first marketing application in any jurisdiction, and the Company believes the additional data will strengthen the application and expand the evidence available for regulatory review.
The March 2027 filing target updates the previously announced December 2026 timetable, allowing the additional data to be included. Health Canada has confirmed it has no concerns with the revised timing.
The planned filing follows completion of the pre-submission process and alignment with Health Canada on the proposed submission content and structure. The expanded package will combine the Phase 2b PARADIGM results published in JAMA Neurology with a new neurofilament light chain (NfL) analysis and additional unpublished data from the Phase 2b PARADIGM trial. The Company expects the NfL analysis to provide further biomarker evidence supporting the clinical findings observed in PARADIGM. In the new analysis, PrimeC-treated participants demonstrated a greater reduction in NfL compared to placebo, with an even more pronounced effect observed in participants with higher baseline functionality. Additional statistical analyses are underway to further characterize these findings and support their incorporation into the planned submission to Health Canada.
Following acceptance of the NDS for review, Health Canada’s standard review target for an NDS is approximately 300 calendar days. If approved, PrimeC would receive its first regulatory authorization and would address a population of approximately 4,000 Canadians living with ALS, with approximately 1,000 new diagnoses each year. In parallel, the Company is advancing discussions with potential commercialization partners for Canada.
"Neurofilament light chain is one of the most widely used measures of neuronal injury in ALS, and adding this analysis to the PARADIGM results gives Health Canada a broader body of evidence on which to evaluate PrimeC’s potential benefit for people living with ALS," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "Canada is our nearest path to patients, and our priority is to submit the most complete application we can. In parallel, we are preparing for the FDA-cleared U.S. Phase 3 PARAGON trial."
About NeuroSense
NeuroSense Therapeutics is a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company’s lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.
Results from NeuroSense’s Phase 2b PARADIGM study of PrimeC in ALS have been published in JAMA Neurology.
NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate its pivotal Phase 3 clinical trial (PARAGON) in ALS, to be conducted primarily in the United States. The Company is working with the FDA on an optimized design for the study.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
About PrimeC
PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to target several key mechanisms that contribute to neuronal degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation, with the potential to inhibit disease progression.
About ALS
Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes progressive paralysis and, typically, death within 3 years of symptom onset. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "may," "plan," "potential," "target," "will," or similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, without limitation, statements regarding the Company’s planned New Drug Submission (NDS) to Health Canada for PrimeC, the anticipated timing of such submission, the completion and incorporation of additional clinical and biomarker analyses, including neurofilament light chain (NfL), the potential contribution of such analyses to the regulatory assessment of PrimeC, the anticipated regulatory review process and timelines, the Company’s discussions with potential commercialization partners for Canada, the potential patient population for PrimeC and estimated annual ALS diagnoses in Canada, and the Company’s plans to advance its Phase 3 PARAGON clinical trial in ALS. Forward-looking statements are based on the Company’s current expectations and assumptions and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, delays in completing the additional analyses or preparing and submitting the NDS, the possibility that the additional data may not provide the anticipated supporting evidence, uncertainties regarding the acceptance, review, timing and outcome of the NDS, the possibility that Health Canada may request additional information or clinical studies, delays in initiating or conducting the PARAGON trial, the possibility that the Company will not enter into a commercialization partnership for Canada on acceptable terms, or at all, uncertainty in estimates of ALS incidence and the potential patient population in Canada, the Company’s ability to obtain sufficient financing to support its operations and clinical development programs, the Company’s ability to maintain its listing on Nasdaq and other risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission (SEC). There can be no assurance that the NDS will be submitted within the anticipated timeframe, that Health Canada’s review will be completed within the standard review period, or that PrimeC will receive regulatory approval. Additional information concerning these and other risks is included under "Risk Factors" in the Company’s Annual Report on Form 20-F filed with the SEC on March 31, 2026, and in its subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.
Investor Relations and Media Contact: NeuroSense Therapeutics Ltd., info@neurosense-tx.com | +972 (0)9 799 6183